CD40.RBDv vaccine / EnnoDC - LARVOL DELTA

Immunogenicity and protective efficacy on non-adjuvanted CD40-targeting SARS-CoV-2 vaccines in non-human primates. (PubMed, EBioMedicine) - "These findings support the ability of AMV targeting CD40 to induce strong, long-lasting responses against adapted antigens and broad protection against evolving SARS-CoV-2 variants without requiring adjuvant. These two vaccine candidates are currently under clinical testing."

IO biomarker • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD40

SOLVE-01: An Experimental Medicine Multicenter Trial to Evaluate the Safety and Immunogenicity of Experimental Versus Authorized SARS-CoV-2 Vaccine Candidates as a Booster Dose in Healthy Participants Previously Vaccinated With Authorized mRNA SARS-CoV-2 Vaccines. (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: ANRS, Emerging Infectious Diseases | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

SOLVE-01: An Experimental Medicine Multicenter Trial to Evaluate the Safety and Immunogenicity of Experimental Versus Authorized SARS-CoV-2 Vaccine Candidates as a Booster Dose in Healthy Participants Previously Vaccinated With Authorized mRNA SARS-CoV-2 Vaccines. (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: ANRS, Emerging Infectious Diseases

New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers. (clinicaltrials.gov) - P1/2 | N=215 | Recruiting | Sponsor: ANRS, Emerging Infectious Diseases | Active, not recruiting ➔ Recruiting

Enrollment open • IO biomarker • Infectious Disease • Novel Coronavirus Disease

Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers. (clinicaltrials.gov) - P1/2 | N=215 | Active, not recruiting | Sponsor: ANRS, Emerging Infectious Diseases | Recruiting ➔ Active, not recruiting

Enrollment closed • IO biomarker • Infectious Disease • Novel Coronavirus Disease • CD4 • CD8

Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers. (clinicaltrials.gov) - P1/2 | N=240 | Recruiting | Sponsor: ANRS, Emerging Infectious Diseases | Not yet recruiting ➔ Recruiting | Initiation date: Feb 2024 ➔ May 2024

Enrollment open • Trial initiation date • Infectious Disease • Novel Coronavirus Disease